Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Turn Therapeutics Inc ( (TTRX) ) just unveiled an announcement.
On February 17, 2026, Turn Therapeutics, Inc., a clinical-stage biotechnology company specializing in targeted inflammatory and immunology therapies for dermatologic conditions, announced the appointment of Robert Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Senior Advisor of Health Policy and Regulatory Affairs. Redfield will advise on clinical development, public health implications, and regulatory strategy for Turn’s lead candidate GX-03, now in Phase 2 trials for moderate-to-severe atopic dermatitis, a move that bolsters the company’s regulatory expertise and could strengthen its positioning in the competitive dermatology therapeutics market.
The most recent analyst rating on (TTRX) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
Spark’s Take on TTRX Stock
According to Spark, TipRanks’ AI Analyst, TTRX is a Neutral.
Overall score is held down primarily by weak financial performance (no revenue, ongoing cash burn, and negative equity indicating financing risk). Technicals are a notable offset with bullish momentum (price above key moving averages and positive MACD). Valuation remains a headwind due to negative earnings and no dividend support.
To see Spark’s full report on TTRX stock, click here.
More about Turn Therapeutics Inc
Turn Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead investigational product, GX-03, is a first-in-class, non-systemic topical inhibitor in development for moderate-to-severe atopic dermatitis and other inflammatory dermatologic conditions.
Average Trading Volume: 65,966
Current Market Cap: $103.4M
See more insights into TTRX stock on TipRanks’ Stock Analysis page.